Sapience Therapeutics
PrivateLast Round
Grant
May 4, 2023
Total Funding Raised
$66M
Company Overview
Sapience Therapeutics is a biotechnology company that develops peptide-based therapeutics targeting oncogenic and immune dysregulation to combat cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sapience Therapeutics Comparables
Compare Sapience Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Circle Pharma | 80% | |
| Peptomyc | 78% | |
| Parabilis Medicines | 76% |
Sapience Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 4, 2023 | ||||
| Grant | Oct 4, 2022 | ||||
| Series B | May 31, 2022 | ||||
| Grant | Oct 12, 2021 | ||||
| Grant | May 18, 2021 | ||||
Private Placement | Nov 17, 2020 |
Key People
Founding team and executive leadership
Sapience Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| TaiAn Technologies Corp. | Series A |
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Columbia University in the City of New York | Series A |
| Eshelman Ventures | Private Placement, Series A, Series B |
| Columbia Technology Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 73% MoM.
- Apr 13, 2026
Attended the 25th Annual Needham Virtual Healthcare Conference.
Sapience Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sapience Therapeutics's valuation, stock price, and market status.
Is Sapience Therapeutics a public or private company?
Sapience Therapeutics is a private company.
What is the current stock price of Sapience Therapeutics?
Sapience Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Sapience Therapeutics worth (valuation)?
Valuation information for Sapience Therapeutics is not publicly available.
Can I buy Sapience Therapeutics stock?
Sapience Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sapience Therapeutics's last funding round?
Sapience Therapeutics's most recent funding round was Grant on May 4, 2023.
Who are the main investors in Sapience Therapeutics?
Key investors in Sapience Therapeutics include Eshelman Ventures, NexPoint Capital, Inc..
Will Sapience Therapeutics IPO soon?
No public IPO plans have been announced for Sapience Therapeutics.
How can I track Sapience Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sapience Therapeutics's secondary market activity and sign up for updates.